262 completed, 85 recruiting, 76 unknown, 50 terminated. 264 Phase 2, 125 Phase 1, 65 Phase 3, 55 Not applicable, 9 Phase 4.
Follow Histiocytosis: new trials by email Literature Review of Histiocytosis trials Research Report on Histiocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis | Phase 2 / Phase 3 | Not yet recruiting | Azafaros B.V. | 218 | 2026-12-10 | 2026-10-21 |
| Cardiac Imaging in Systemic Disorders: the ORACLES Registry data collection - Lupus | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1500 | 2026-11-01 | 2026-02-13 | |
| A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents treated group - Histiocytosis,Langerhans-Cell | Phase 1 / Phase 2 | Enrolling by invitation | Second Affiliated Hospital of Wenzhou Medical University | 2 | 2026-10-20 | 2026-10-22 |
| Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH) Intravenous Immunoglobulin (IVIg) therapy, Intravenous Dexamethasone (IVD) therapy, Targeted antimicrobial therapy & standard care - Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis | Phase 3 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 116 | 2026-10-15 | 2026-10-06 |
| CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) Rapcabtagene autoleucel (YTB323) - Large-cell Lymphoma | Phase 1 | Not yet recruiting | Stanford University | 20 | 2026-09-01 | 2026-08-27 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement pirtobrutinib+MTX+immunolchemotherapy - Pirtobrutinib, Immunochemotherapy | Phase 2 | Not yet recruiting | Pengpeng Xu | 24 | 2026-09-01 | 2026-09-11 |
| Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs - Bone Marrow Failure, Hemoglobinopathies | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 40 | 2026-09-01 | 2026-06-22 |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Luvometinib, Luvometinib, Cytarabine. - Langerhans Cell Histiocytosis | Phase 2 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 30 | 2026-06-30 | 2026-07-27 |
| Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions Luvometinib - Langerhans Cell Histiocytosis (LCH) | Not applicable | Recruiting | West China Second University Hospital | 62 | 2026-06-19 | 2026-01-27 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Sinocelltech Ltd. | 101 | 2026-06-04 | 2026-08-13 |
| All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis ATRA - Hemophagocytic Lymphohistiocytosis (HLH) | Phase 2 / Phase 3 | Not yet recruiting | Beijing Anzhen Hospital | 30 | 2026-06-01 | 2026-06-04 |
| Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP CL-Pola-R-CHP - DHL, THL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-05-01 | 2026-04-27 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
Showing 20 of 574. Sign in to see all of them.
Dendritic Cell Sarcoma, Interdigitating (298) · Burkitt Lymphoma (196) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (185) · Lymphoma, Large B-Cell, Diffuse (169) · Lymphoma (167) · Lymphoma, Non-Hodgkin (162) · Lymphoma, Follicular (150) · Recurrence (150) · Leukemia, Lymphocytic, Chronic, B-Cell (139) · Lymphoma, Mantle-Cell (139) · Lymphoma, B-Cell, Marginal Zone (133) · Leukemia (125) · Lymphoma, Large-Cell, Immunoblastic (124) · Hodgkin Disease (119) · Leukemia, Myeloid, Acute (113)
Hemic and Lymphatic Diseases (574) · Lymphatic Diseases (572) · Neoplasms by Histologic Type (352) · Neoplasms (329) · Immune System Diseases (323) · Immunoproliferative Disorders (317) · Histiocytic Disorders, Malignant (303) · Lymphoproliferative Disorders (301) · Pathological Conditions, Signs and Symptoms (249) · Pathologic Processes (242) · Hematologic Diseases (236) · Lymphoma, B-Cell (225) · Disease Attributes (222) · Virus Diseases (212)
Cyclophosphamide (94) · Etoposide (55) · fludarabine phosphate (50) · Busulfan (43) · Cyclosporine (40) · Filgrastim (40) · Antilymphocyte Serum (37) · Peripheral Blood Stem Cell Transplantation (36) · Methotrexate (35) · Mycophenolic Acid (35) · Radiotherapy (33) · Melphalan (31) · Whole-Body Irradiation (31) · Methylprednisolone (27) · Rituximab (27)
National Cancer Institute (NCI) (39) · Fred Hutchinson Cancer Center (35) · Beijing Friendship Hospital (20) · Masonic Cancer Center, University of Minnesota (19) · Memorial Sloan Kettering Cancer Center (17) · Children's Oncology Group (15) · Assistance Publique - Hôpitaux de Paris (14) · Case Comprehensive Cancer Center (11) · Roswell Park Cancer Institute (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Swedish Orphan Biovitrum (8) · Baylor College of Medicine (6) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (6) · M.D. Anderson Cancer Center (6) · Peking Union Medical College Hospital (6)
United States (357) · China (85) · France (46) · Italy (38) · United Kingdom (36) · Canada (33) · Germany (30) · Australia (28) · Spain (23) · Puerto Rico (19) · Switzerland (18) · Brazil (11) · Netherlands (11) · Poland (11) · Turkey (Türkiye) (9)
Forbes D Porter, M.D. (6) · Zhao Wang, MD (6) · Philip L. McCarthy, MD (5) · Brenda Sandmaier (4) · David Maloney (4) · Eli Diamond, MD (4) · Kenneth G. Lucas, MD (4) · Tanya Trippett, MD (4) · Anna Raciborska (3) · Claudio G. Brunstein, MD, PhD (3) · David G. Savage, MD (3) · Ephraim J. Fuchs, MD (3) · K. Scott Baker (3)
PMID 31401903, PMID 32499241, PMID 36884302, PMID 31513482, PMID 32106306, PMID 36279795, PMID 37216396, PMID 37486616, PMID 37731389, PMID 38662147, PMID 40525490, PMID 15049016, PMID 21586746, PMID 23589673, PMID 29263218, PMID 30693828, PMID 32374962, PMID 33958797, PMID 34387740, PMID 34398557, PMID 34515338, PMID 34687939, PMID 37001971, PMID 38501389, PMID 38501390, PMID 40167581, PMID 40751881, PMID 41035796, PMID 10632319, PMID 10673703, PMID 10820362, PMID 12171484, PMID 14556926, PMID 15107815, PMID 15466923, PMID 15659500, PMID 16533779, PMID 16864853, PMID 17119113, PMID 17132719, PMID 17138821, PMID 17439836, PMID 17515574, PMID 17610262, PMID 17889355, PMID 17910637, PMID 17959855, PMID 18079362, PMID 18166803, PMID 18371107
U10CA180886 (14), P30CA015704 (11), U01CA097452 (9), P30CA006973 (7), P30CA043703 (7), P01CA015396 (5), P01CA018029 (5), 2015 (4), P30CA008748 (4), P30CA016672 (4), P30CA033572 (4), U10CA098543 (4), 2014 (3), P01CA078902 (3), P30CA068485 (3)